Success Metrics

Active Trials
8(100%)

Phase Distribution

Ph phase_2
3
38%
Ph phase_1
5
63%

Phase Distribution

5

Early Stage

3

Mid Stage

0

Late Stage

Phase Distribution8 total trials
Phase 1Safety & dosage
5(62.5%)
Phase 2Efficacy & side effects
3(37.5%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

8

trials recruiting

Total Trials

8

all time

Status Distribution
Active(8)

Detailed Status

Active, not recruiting5
Recruiting3

Development Timeline

Analytics

Development Status

Total Trials
8
Active
8
Success Rate
N/A
Most Advanced
Phase 2

Trials by Phase

Phase 15 (62.5%)
Phase 23 (37.5%)

Trials by Status

recruiting338%
active_not_recruiting563%

Recent Activity

8 active trials
Showing 5 of 8
recruitingphase_1

A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell ( CAR-T) Therapy in Subjects With Non-relapsing and Progressive Forms of Multiple Sclerosis

NCT06138132
recruitingphase_1

A Phase 1 Study of Anitocabtagene Autoleucel for the Treatment of Subjects With Non-oncology Plasma Cell-related Diseases

NCT06626919
recruitingphase_2

KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia Gravis

NCT06193889
active_not_recruitingphase_2

KYSA-8: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Treatment Refractory Stiff Person Syndrome

NCT06588491
active_not_recruitingphase_1

KYSA-1: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Refractory Lupus Nephritis

NCT05938725
View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials
NCT06138132Phase 1

A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell ( CAR-T) Therapy in Subjects With Non-relapsing and Progressive Forms of Multiple Sclerosis

Recruiting
NCT06626919Phase 1

A Phase 1 Study of Anitocabtagene Autoleucel for the Treatment of Subjects With Non-oncology Plasma Cell-related Diseases

Recruiting
NCT06193889Phase 2

KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia Gravis

Recruiting
NCT06588491Phase 2

KYSA-8: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Treatment Refractory Stiff Person Syndrome

Active Not Recruiting
NCT05938725Phase 1

KYSA-1: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Refractory Lupus Nephritis

Active Not Recruiting
NCT06342960Phase 1

KYSA-3: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Refractory Lupus Nephritis

Active Not Recruiting
NCT06400303Phase 1

KYSA-5: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Systemic Sclerosis

Active Not Recruiting
NCT06384976Phase 2

KYSA-7: A Study of Anti-CD19 CAR T-Cell Therapy, in Subjects With Refractory Primary and Secondary Progressive Multiple Sclerosis

Active Not Recruiting

All 8 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
8